Drug Profile
SPT 201
Latest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator Valeant Pharmaceuticals International
- Developer Bausch Health Companies
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Decreased libido
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for clinical-Phase-Unknown development in Decreased-libido in USA
- 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
- 13 Jan 2016 Clinical trials in Decreased libido in USA (unspecified route) before January 2016